Web16 lug 2024 · In a study published in JAMA Oncology, Dr. Igor Puzanov took a 10-year look at pembrolizumab use in patients with advanced melanoma “The study reinforces the fact that immunotherapy can significantly extend the life of patients with melanoma and even lead to cures," said Dr. Puzanov. Web7 set 2024 · Antoni Ribas 1 , Reinhard Dummer 2 , Igor Puzanov 3 , Ari VanderWalde 4 , Robert H I Andtbacka 5 , Olivier Michielin 6 , Anthony J Olszanski 7 , Josep Malvehy 8 , Jonathan Cebon 9 , Eugenio Fernandez 10 , John M Kirkwood 11 , Thomas F Gajewski 12 , Lisa Chen 13 , Kevin S Gorski 14 , Abraham A Anderson 13 , Scott J Diede 15 , Michael …
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic …
WebDr. Igor Puzanov is a Medical Oncology Specialist in Buffalo, New York. He graduated with honors in 1991. Having more than 32 years of diverse experiences, especially in … WebDr. Igor Puzanov, MD. Medical Oncology • Male • Age 55. Dr. Igor Puzanov, MD is a Medical Oncology Specialist in Nashville, TN and has over 32 years of experience in the … オガネソン 記号
Progression-free Survival and Biomarker Correlates - Nektar
Web1 nov 2024 · Igor Puzanov, MD, MSCI, FACP. Talimogene laherparepvec (T-VEC; Imlygic) gained FDA approval in 2015 as a single agent for the treatment of advanced-stage unresectable melanoma, but new evidence has shown that the first in-class oncolytic immunotherapy may be even more efficacious in combination, explained … Web9 dic 2024 · BUFFALO, N.Y. — Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, … Web30 apr 2012 · Dr. Igor Puzanov, MD, is a Hematology/Oncology specialist in Nashville, Tennessee. He attended and graduated from medical school in 1991, having over 32 years of diverse experience, especially in Hematology/Oncology. He is affiliated with many hospitals including Vanderbilt University Hospital. papetes arezzo